2Berry C,Tardif JC,Bourassa MG,et al. Coronary heart disease in patients with diabetes. JACC, 2007,49 : 631-642.
3Buse JB, Ginsberg HN, Bakris GI, et al. Primary prevention of cardiovascular disease in people with diabetes mellitus;A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care, 2007,30 : 162- 172.
4Preventing and managing diabetic complications in elderly patients. Cleve Clin J Med,2008,75:153-158.
5Insull WJr. The pathology of atheroselerosis: plaque development and plaque responses to medical treatment. Am J Med, 2009,122 : S3-S14.
6Buse JB,Bigger JT,Byington RP,et al. Action to Control Cardiovascular Risk in Diabetes(ACCORD) trial:design and methods. Am J Cardiol,2007,99:S21-S33.
7ADVANCE Collaborative Group. Effects of a fixed combination of peridopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus(the ADVANCE trial). Lancet, 2007,370 : 829-840.
8Saremi A, Anderson R J, Luo P, et al. Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Atherosclerosis, 2009, 203 : 610- 614.
9Lafuma A,Colin X, Solesse A. Cost-effectiveness of atorvasta tin in the prevention of cardiovascular events in diabetic pa tients:A French adaptation of CARDS. Arch Cardiovasc Dis, 2008,101:327-332.
10Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis [ J]. Circulation, 2004,109 (21 Suppll ) : II 27- II 33.
